Tirzepatide offers proven effectiveness with established safety profiles
For Medicare beneficiaries, the White House deal promises to cap GLP-1 out-of-pocket costs at $50 per month
Early evidence suggests GLP-1 medications may also reduce neuroinflammation, which has been linked to disrupted sleep regulation in individuals with metabolic disease (ref, ref)
The tirzepatide weight loss results show how the dual-receptor mechanism produces additional weight loss beyond what semaglutide alone achieves
For adults who have struggled with appetite, cravings, insulin resistance, or weight that returns after dieting, GLP-1 treatment may be worth discussing with a qualified clinician
For weight management, documenting baseline weight, current weight, and the timeline of treatment provides objective data for assessment